Mouser Electronics and Grant Imahara Explore Crowd Funding for Innovators in Newest “Engineering Big Ideas” Video
20.11.2019 19:54:00 EET | Business Wire | Press release
Today Mouser Electronics Inc. and celebrity engineer Grant Imahara unveiled the third video in the Engineering Big Ideas series, part of their award-winning Empowering Innovation Together™ program. To watch the third video in the series, go to https://mou.sr/EIT2019-3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191120005734/en/
Join global distributor Mouser Electronics and engineer spokesperson Grant Imahara as they travel to Portland, Ore., to meet with Josh Lifton, President of Crowd Supply, in the latest Engineering Big Ideas video, part of Mouser’s Empowering Innovation Together program. Imahara and Lifton look at the processes and resources available to help innovators best determine whether it’s feasible to manufacture their ideas. To learn more, visit www.mouser.com/empowering-innovation/Engineering-Big-Ideas. (Photo: Business Wire)
In part three, Imahara meets with Josh Lifton, President of Crowd Supply, a successful crowd funding platform based in Portland, Ore. Crowd Supply partners with creators and entrepreneurs who utilize the service to tap pools of small contributions from the public to fund ideas. The company also provides mentorship from their staff of product development veterans, filling a role similar to a business incubator.
“In the prototype stage, creators are often plagued by funding challenges and face design bottlenecks,” says Glenn Smith, President and CEO of Mouser Electronics. “Platforms like Crowd Supply give designers access to a wealth of monetary and intellectual resources, opening avenues to innovation not previously accessible.”
“By helping address major issues in funding and launching products in general, Crowd Supply helps level the playing field for creators by sharing these essential resources,” adds Imahara.
Imahara’s and Lifton’s conversation takes a look at the processes and resources available to help innovators best determine whether it’s feasible to manufacture their ideas. Throughout their discussion, they examine the process of taking an idea from concept through to prototype, to eventually a product that someone will want to buy or invest in.
The Engineering Big Ideas series is sponsored by Mouser’s valued suppliers Analog Devices, Intel ®, Microchip Technology and Molex. The global electronic component distributor is teaming up with engineer Grant Imahara for the fifth consecutive year to present the Engineering Big Ideas series, which explores the process of turning an idea into a product and examines the path to commercialization — from discovery to design and eventually development.
The Empowering Innovation Together program has been one of the most recognized and notable electronic component educational programs since 2015, highlighting a range of innovative developments from IoT and smart cities of the future to robotics technologies.
To learn more about this and all of Mouser’s Empowering Innovation Together series, visit www.mouser.com/empowering-innovation and follow Mouser on Facebook and Twitter.
About Mouser Electronics
Mouser Electronics, a Berkshire Hathaway company, is an award-winning, authorized semiconductor and electronic component distributor focused on rapid New Product Introductions from its manufacturing partners for electronic design engineers and buyers. The global distributor's website, Mouser.com, is available in multiple languages and currencies and features more than 5 million products from over 800 manufacturers. Mouser offers 27 support locations around the world to provide best-in-class customer service and ships globally to over 630,000 customers in 223 countries/territories from its 750,000 sq. ft. state-of-the-art facility south of Dallas, Texas. For more information, visit www.mouser.com.
About Grant Imahara
Well known in the engineering community, Grant Imahara has paired his engineering expertise with a successful TV and film career. In addition to his roles on MythBusters and BattleBots, Imahara has worked on many famous robotic characters, including R2-D2 from Star Wars, the talking robot skeleton sidekick Geoff Peterson from The Late Late Show with Craig Ferguson, and the Energizer Bunny.
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. Intel is a registered trademark of Intel Corporation in the United States and other countries. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005734/en/
Contact information
Further information, contact:
Kevin Hess, Mouser Electronics
Senior Vice President of Marketing
(817) 804-3833
Kevin.Hess@mouser.com
For press inquiries, contact:
Kelly DeGarmo, Mouser Electronics
Manager, Corporate Communications and Media Relations
(817) 804-7764
Kelly.DeGarmo@mouser.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom